Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-13 11:20 am Purchase | 2025-06-30 | 13G | Beta Bionics, Inc. BBNX | Sands Capital Life Sciences Pulse Fund II L.P. | 3,570,113 8.200% | 415,704 (+13.18%) | Filing History |
| 2025-08-13 11:17 am Unchanged | 2025-06-30 | 13G | Inhibikase Therapeutics, Inc. IKT | Sands Capital Life Sciences Pulse Fund II L.P. | 10,950,000 14.700% | 0 (Unchanged) | Filing History |
| 2025-08-13 11:12 am Purchase | 2025-06-30 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV | Sands Capital Life Sciences Pulse Fund II L.P. | 2,122,605 6.800% | 469,999 (+28.44%) | Filing History |
| 2025-04-09 4:10 pm Purchase | 2025-04-02 | 13G | Beta Bionics, Inc. BBNX | Sands Capital Life Sciences Pulse Fund II L.P. | 3,154,409 7.300% | 3,154,409 (New Position) | Filing History |
| 2024-10-25 5:50 pm Purchase | 2024-10-21 | 13G | Inhibikase Therapeutics, Inc. IKT | Sands Capital Life Sciences Pulse Fund II L.P. | 10,950,000 16.300% | 10,950,000 (New Position) | Filing History |
| 2023-06-22 4:32 pm Sale | 2023-06-20 | 13D | DICE Therapeutics, Inc. DICE | Sands Capital Life Sciences Pulse Fund II L.P. | 1,886,470 4.000% | -1,262,500 (-40.09%) | Filing History |
| 2022-11-25 4:25 pm Purchase | 2022-11-15 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV | Sands Capital Life Sciences Pulse Fund II L.P. | 1,652,606 7.900% | 1,652,606 (New Position) | Filing History |
| 2021-09-24 6:12 pm Purchase | 2021-09-17 | 13D | DICE Therapeutics, Inc. DICE | Sands Capital Life Sciences Pulse Fund II L.P. | 3,148,970 8.700% | 3,148,970 (New Position) | Filing History |